8-K: Haemonetics Director Charles Dockendorff to Step Down

Long-serving director Charles J. Dockendorff has announced he will not seek re-election at the upcoming 2026 Annual Meeting of Shareholders.

Summary

• Charles J. Dockendorff informed the company on April 27, 2026, that he will not stand for re-election to the Board of Directors.
• Dockendorff has been a member of the Board since 2014, providing over a decade of oversight.
• He currently serves as a member of the Audit Committee and the Governance and Compliance Committee.
• The transition will be effective as of the 2026 Annual Meeting of Shareholders.
• The departure is not the result of any disagreement with the company regarding operations, policies, or practices.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the loss of an experienced director is notable, the amicable nature of the departure and the advance notice suggest a stable governance environment.

Positives

• The departure is amicable and not due to any internal conflicts or disagreements.
• Dockendorff is providing sufficient notice, allowing for an orderly succession process.
• His continued service until the 2026 Annual Meeting ensures stability in committee functions during the transition period.

Negatives

• Loss of a long-tenured director with 12 years of institutional knowledge and experience.
• Creates vacancies on two critical board committees: Audit and Governance and Compliance.

Risks

• Potential loss of continuity in oversight within the Audit and Governance committees.
• The company must successfully identify and recruit a replacement with comparable financial and governance expertise.

Future Outlook

The company will proceed with its 2026 Annual Meeting of Shareholders without Mr. Dockendorff on the ballot, likely necessitating the nomination of a new director to maintain board and committee composition.

Management Comments

• Mr. Dockendorffs decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company.

Industry Context

StockSavvy.ai notes that board refreshes are a standard part of corporate governance in the healthcare and medical technology sectors, often used to bring in new expertise as companies pivot toward digital health and advanced blood management technologies.

Comparison to Industry Standards

• The 12-year tenure of Mr. Dockendorff is consistent with industry averages for independent directors in the S&P 500.
• The use of an 8-K filing for director departures is a standard regulatory requirement under Item 5.02.
• The clear statement regarding the lack of disagreement is a standard best practice to maintain investor confidence during leadership transitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will vote on a new board slate at the 2026 Annual Meeting.
• Board committees will see a change in membership, potentially affecting oversight dynamics.

Next Steps

• Nomination of a replacement director for the 2026 Annual Meeting.
• Reconstitution of the Audit and Governance and Compliance Committees following the 2026 Annual Meeting.

Key Dates

Recommendation

The announcement of a director's retirement in an amicable manner is a routine governance event and does not fundamentally alter the company's valuation or strategic trajectory.

Keywords

Haemonetics, HAE, Board of Directors, Corporate Governance, Director Retirement, Audit Committee, Medical Devices